Ethyl 4,4,4-trifluoroacetoacetate

We are Ethyl 4,4,4-trifluoroacetoacetate CAS:372-31-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:  Ethyl 4,4,4-trifluoroacetoacetate
CAS.NO:372-31-6
Synonyms: 
ETHYL TRIFLUOROACETOACETATE
Ethyl4,4,-Trifluoroacetoacetate
Butanoic acid, 4,4,4-trifluoro-3-oxo-, ethyl ester
4,4,4-trifluoro-3-oxobutanoic acid ethyl ester
Ethyl 4,4,4-trifluor
Ethyl 4,4,4-trifluoro-3-oxobutanoate
ETHYL 4,4,4-TRIFLUOROACETOACTATE
ethyl 4,4,4-trifluoro-acetoacetate
ethyl 3-trifluoromethyl-3-oxopropionate
ethyl 4,4,4-trifluoro-3-ketobutyrate
Ethyl 3-oxo-4,4,4-trifluorobutyrate
ethyl 3-trifluoromethyl-3-oxopropanoate
4,4,4-Trifluoroacetoacetic Acid Ethyl Ester

Molecular Formula: C6H7F3O3
Molecular Weight:184.11300

Physical and Chemical Properties:
Density: 1.259
Boiling point: 129-130 ° C (lit.)
Melting point: -39 ° C
Flash point: 84 ° F
Refractive index: 1.363

Specification:
Appearance:Colorless transparent liquid
Purity:≥98%
Moisture(%):≤0.1

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:
Intermediates of Levetiracetam  CAS:102767-28-2

Related News: Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.1,3-Bis(2,4-Diaminophenoxy)Propane 4HCl Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.(4S)-4-(Phenylthio)-L-proline Hydrochloride Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.O-[(Ethoxycarbonyl)cyanomethyleneamino]-N,N,N',N'-tetramethyluronium Tetrafluoroborate CAS:136849-72-4 China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases.